Home
Concord Biotech Ltd PE Ratio
![Image](/insights/_next/image?url=https%3A%2F%2Fstorage.googleapis.com%2Fassets.cdp.blinkx.in%2FBlinkx_Website%2Ficons%2Fconcord-biotech-ltd.png&w=128&q=75)
Concord Biotech Ltd
NSE: CONCORDBIO
PE
Key Highlights
- The P/E Ratio of Concord Biotech Ltd is 54.3 as of 15 Feb 9.00 AM .
- The P/E Ratio of Concord Biotech Ltd changed from 51.7 on March 2024 to 51.7 on March 2024 . This represents a CAGR of 0.00% over 1 years.
- The Latest Trading Price of Concord Biotech Ltd is ₹ 1693 as of 14 Feb 15:30 .
- The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
- The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.3. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.
Historical P/E Ratio of Concord Biotech Ltd
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
Historical P/E Ratio of Concord Biotech Ltd
Company Fundamentals for Concord Biotech Ltd
![Image](/insights/_next/image?url=https%3A%2F%2Fstorage.googleapis.com%2Fassets.cdp.blinkx.in%2FBlinkx_Website%2Ficons%2Fconcord-biotech-ltd.png&w=128&q=75)
Concord Biotech Ltd
NSE: CONCORDBIO
Share Price
Market Price of Concord Biotech Ltd
1M
1Y
3Y
5Y
Last Ten Days Market Price
Date | |
---|---|
14 Feb 2025 | 1693.2 |
13 Feb 2025 | 2109.95 |
12 Feb 2025 | 2120.75 |
11 Feb 2025 | 2144.55 |
10 Feb 2025 | 2235.25 |
07 Feb 2025 | 2342.25 |
06 Feb 2025 | 2343.65 |
05 Feb 2025 | 2270.6 |
04 Feb 2025 | 2238.75 |
03 Feb 2025 | 2141.5 |
SWOT Analysis Of Concord Biotech Ltd
BlinkX Score for Concord Biotech Ltd
Asset Value vs Market Value of Concord Biotech Ltd
Market Value
₹ 0
Asset Value
₹ 0
* All values are in ₹ crores
Competitive Comparison of P/E Ratio
Company | Market Cap | PE Ratio |
---|
Concord Biotech Ltd | 17713 | 54.29 |
Sun Pharmaceuticals Industries Ltd | 409003 | 34.7 |
Divis Laboratories Ltd | 154939 | 75.0 |
Cipla Ltd | 117835 | 23.6 |
Torrent Pharmaceuticals Ltd | 101918 | 54.7 |
Dr Reddys Laboratories Ltd | 99785 | 18.6 |
Company | |
---|---|
Concord Biotech Ltd | 17713 |
Sun Pharmaceuticals Industries Ltd | 409003 |
Divis Laboratories Ltd | 154939 |
Cipla Ltd | 117835 |
Torrent Pharmaceuticals Ltd | 101918 |
Dr Reddys Laboratories Ltd | 99785 |
PE Ratio of Concord Biotech Ltd Explained
₹17713
Market cap
₹326
Earnings
54.3X
PE Ratio
The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.
P/E Ratio Formula
P/E ratio = (CMP of share/ Earning per share)
Types of Price to Earning Ratio
1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.
PE Ratio of Pharmaceuticals Industry over time
PE Ratio of Top Sectors
Historical Market Cap of Concord Biotech Ltd
Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore
Historical Market Cap of Concord Biotech Ltd
Historical Revenue, EBITDA and Net Profit of Concord Biotech Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
Historical Revenue, EBITDA and Net Profit of Concord Biotech Ltd
Revenue
EBITDA
Net Profit
Historical Dividend Payout of Concord Biotech Ltd
Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.
Historical Dividend Payout of Concord Biotech Ltd
About Concord Biotech Ltd
- Concord Biotech Limited was originally incorporated as Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies.
- Thereafter, name of the Company was changed to Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.
- Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products.
Concord Biotech Ltd News Hub
Concord Biotech consolidated net profit rises 9.36% in the June 2024 quarter
Net profit of Concord Biotech rose 9.36% to Rs 59.59 crore in the quarter ended June 2024 as against
Read more
09 Aug 24
Volumes jump at Concord Biotech Ltd counter
K E C International Ltd, Sonata Software Ltd, TV18 Broadcast Ltd, ZF Commercial Vehicle Control Syst
Read more
29 Aug 24
Concord Biotech to conduct board meeting
Concord Biotech will hold a meeting of the Board of Directors of the Company on 11 November 2024 Pow
Read more
06 Nov 24
Concord Biotech consolidated net profit rises 18.17% in the September 2024 quarter
Net profit of Concord Biotech rose 18.17% to Rs 95.74 crore in the quarter ended September 2024 as a
Read more
11 Nov 24